Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115439 | 0.84 | CASP3 (0.55) | CASP3CHRM5MEN1ALDH1A1GAA | |
| SCHEMBL5112878 | 0.84 | CASP3 (0.51) | CASP3CHRM5MEN1ALDH1A1GAA | |
| SCHEMBL5126848 | 0.81 | CASP3 (0.51) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5120964 | 0.79 | CASP3 (0.51) | CASP3CHRM5MEN1ALDH1A1GAA | |
| SCHEMBL2570381 | 0.78 | CASP3 (0.63) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5114960 | 0.78 | CASP3 (0.54) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5118846 | 0.78 | CASP3 (0.56) | CASP3MEN1ALDH1A1GAAALOX15 | |
| SCHEMBL5126582 | 0.77 | CASP3 (0.50) | CASP3CHRM5ADRA1DADRA1AADRA1B | |
| SCHEMBL5668761 | 0.77 | PPARG (0.52) | PPARGPPARAPLA2G7 | |
| SCHEMBL5111610 | 0.77 | CASP3 (0.58) | CASP3CHRM5ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-15 | — | — | US | disclosed |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180009766-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-01-11 | — | — | US | disclosed |
| EP-3239135-A1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016101927-A1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | 中国科学院上海药物研究所 | 2016-06-30 | — | — | WO | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| EP-2619203-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | Glaxo Group Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| US-7361783-B2 | (2S)-2-ethylphenylpropionic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| EP-1508566-B1 | (2S)-2-ETHYLPHENYLPROPIONIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-20060084702-A1 | (2S)-2-ethylphenylpropionic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| EP-1508566-A1 | (2S)-2-ETHYLPHENYLPROPIONIC ACID DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | CASP3 3472/4885CHRM5 1777/4885ADRA1D 561/4885 |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | CASP3 3472/4885CHRM5 1777/4885ADRA1D 561/4885 |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CASP3 837/4885CHRM5 1961/4885ADRA1D 1855/4885 |
| US-20180009766-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | CASP3 3472/4885CHRM5 1777/4885ADRA1D 561/4885 |
| US-20060084702-A1 | (2S)-2-ethylphenylpropionic acid derivative | PPARA, PPARG, PPARD | CASP3 2013/4885CHRM5 2186/4885ADRA1D 169/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CASP3 837/4885CHRM5 1961/4885ADRA1D 1855/4885 |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | CASP3 3472/4885CHRM5 1777/4885ADRA1D 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.